Literature DB >> 8723325

Iron in liver diseases other than hemochromatosis.

H L Bonkovsky1, B F Banner, R W Lambrecht, R B Rubin.   

Abstract

There is growing evidence that normal or only mildly increased amounts of iron in the liver can be damaging, particularly when they are combined with other hepatotoxic factors such as alcohol, porphyrogenic drugs, or chronic viral hepatitis. Iron enhances the pathogenicity of microorganisms, adversely affects the function of macrophages and lymphocytes, and enhances fibrogenic pathways, all of which may increase hepatic injury due to iron itself or to iron and other factors. Iron may also be a co-carcinogen or promoter of hepatocellular carcinoma, even in patients without HC or cirrhosis. Based on this and other evidence, we hope that the era of indiscriminate iron supplementation will come to an end. Bloodletting, a therapy much in vogue 2 centuries ago, is deservedly enjoying a renaissance, based on our current understanding of the toxic effects of iron and the benefits of its depletion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723325     DOI: 10.1055/s-2007-1007220

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  14 in total

1.  Iron metabolic disorder in chronic hepatitis C: insights from recent evidence.

Authors:  Keisuke Hino; Sohji Nishina; Yuichi Hara
Journal:  Clin J Gastroenterol       Date:  2012-07-31

2.  Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.

Authors:  Tsung-Jung Lin; Chih-Lin Lin; Chaur-Shine Wang; Shu-O Liu; Li-Ying Liao
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

3.  Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study.

Authors:  N Ganne-Carrié; C Christidis; C Chastang; M Ziol; F Chapel; F Imbert-Bismut; J C Trinchet; C Guettier; M Beaugrand
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

4.  Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C.

Authors:  Tsung-Jung Lin; Li-Ying Liao; Shyr-Yi Lin; Chih-Lin Lin; Ting-An Chang
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

5.  Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins.

Authors:  J B Whitfield; L M Cullen; E C Jazwinska; L W Powell; A C Heath; G Zhu; D L Duffy; N G Martin
Journal:  Am J Hum Genet       Date:  2000-03-15       Impact factor: 11.025

Review 6.  Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.

Authors:  H L Bonkovsky; J V Obando
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 7.  Metabolic reprogramming and cell fate regulation in alcoholic liver disease.

Authors:  Hidekazu Tsukamoto
Journal:  Pancreatology       Date:  2015-03-10       Impact factor: 3.996

8.  Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

Authors:  Richard W Lambrecht; Richard K Sterling; Deepa Naishadham; Anne M Stoddard; Thomas Rogers; Chihiro Morishima; Timothy R Morgan; Herbert L Bonkovsky
Journal:  Gastroenterology       Date:  2011-02-15       Impact factor: 22.682

9.  Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells.

Authors:  Wei-Hong Hou; Lisa Rossi; Ying Shan; Jian-Yu Zheng; Richard-W Lambrecht; Herbert-L Bonkovsky
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

10.  Autoimmune Hepatitis: Diagnostic Dilemma When It Is Disguised as Iron Overload Syndrome.

Authors:  Gyanendra K Acharya; Hung-I Liao; Simona Frunza-Stefan; Ronakkumar Patel; Moe Khaing
Journal:  J Clin Exp Hepatol       Date:  2017-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.